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A substantial body of evidence supports the safety and 
effectiveness of hip arthroplasty (HA) in the management 
of end-stage osteoarthritis (OA).1 HA is also the recom-
mended treatment for individuals with end-stage joint 
damage due to an underlying diagnosis of inflammatory 
arthritis.2,3 Reports have suggested that inflammatory 
arthritis can result in poor function postoperatively.4 The 
risk of revision has also been reported to be higher than in 
OA, although results have been conflicting with recent 
meta-analysis indicating that the increased risk of revision 
in inflammatory arthritis was confined to the first 3 months 
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Abstract
Aim: To assess revision rates and postoperative mortality in patients undergoing hip arthroplasty (HA) for inflammatory 
arthritis compared to hip osteoarthritis (OA).
Methods: The analysis was conducted among cases of HA that were recorded in the National Joint Registry for England 
and Wales (NJR) between April 2003 and December 2012 and linked to Office for National Statistics mortality records. 
Procedures were identified where the indication for surgery was listed as seropositive rheumatoid arthritis (RA), 
ankylosing spondylitis (AS), other inflammatory arthritis (otherIA), or OA. 5-year revision risk and 90-day postoperative 
mortality according to indication were compared using Cox regression models adjusted for age, sex, American Society 
of Anaesthesiologists (ASA) grade, year of operation, implant type, and surgical approach.
Results: The cohort included 1457 HA procedures conducted for RA, 615 for AS, 1000 for otherIA, and 183,108 for 
OA. When compared with OA, there was no increased revision risk for any form of inflammatory arthritis (adjusted HRs: 
RA: 0.93 (0.64–1.35); AS: 1.14 (0.73–1.79); otherIA: 1.08 (0.73–1.59)). Postoperative 90-day mortality was increased for 
RA when compared with OA (adjusted HR: 2.86 (1.68–4.88)), but not for AS (adjusted HR: 1.56 (0.59–4.18)) or otherIA 
(adjusted HR: 0.64 (0.16–2.55)).
Conclusions: The revision risk in HA performed for all types of inflammatory arthritis is similar to that for HA 
performed for OA. The 3-fold increased risk of 90-day mortality in patients with RA compared with OA highlights the 
need for active management of associated comorbidities in RA patients during the perioperative period.
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postoperatively.5 The rate of serious systemic infection is 
consistently reported to be higher in patients undergoing 
HA with rheumatoid arthritis (RA),6,7 as is prolonged hos-
pitalisation.8 This increased complication rate following 
primary procedures has not been consistently associated 
with an increase in mortality,5,8 but substantial uncertainty 
remains.
Existing studies of the outcome of surgery in inflamma-
tory arthritis have been limited by their methods of sample 
selection and relatively low sample sizes that have captured 
only few relevant outcomes for rheumatic disease. Reports 
have also focused on RA and often used a loose definition of 
disease that encompasses all types of inflammatory arthritis. 
The risks in ankylosing spondylitis (AS) and the seronega-
tive inflammatory arthropathies have not been considered 
separately. These are distinct diseases: patients with differ-
ent types of inflammatory arthritis are likely to be exposed 
to different degrees of systemic inflammation and treatment 
regimens and have different patterns of bone loss.9,10 All 
these factors have the potential to have a differential impact 
on the rate of complications following surgery, the risk of 
revision and on mortality.
The National Joint Registry (NJR) has been recording 
data on elective arthroplasty in England and Wales since 
2003.11 The dataset of is a sufficient size to explore surgical 
outcomes in relatively uncommon subgroups of patients.
In this analysis, we assess the risk of revision following 
HA in patients with a recorded diagnosis of inflammatory 




The NJR was established in 2003 and captures all HA pro-
cedures including revisions, which can be linked within 
the register to the primary procedure. The NJR dataset also 
is routinely-linked to mortality data from the Office for 
National Statistics (ONS).
Study population
Our initial dataset included data from linkable primary HA 
procedures performed on consenting patients in England 
and Wales between 1 April 2003 and 31 December 2012 for 
whom a valid patient-level identifier was available. Cases of 
revision were only included if a corresponding primary pro-
cedure could be identified within the NJR dataset.
Classification of exposure
The NJR records the indications for surgery for all proce-
dures using a data entry format that allows multiple indica-
tions to be listed for individual case. Data on inflammatory 
arthritis as an indication for surgery were initially recorded 
on the NJR as a separate data field in the core data set. This 
allowed us to classify inflammatory arthritis exposure cat-
egories as: (1) seropositive rheumatoid arthritis (RA); (2) 
ankylosing spondylitis (AS); and (3) other inflammatory 
arthritis (otherIA) (which was defined as seronegative 
rheumatoid arthritis, psoriatic arthritis and other unspeci-
fied inflammatory arthritis). A later version of the core 
dataset used for data collection introduced in December 
2007 (and adopted gradually over subsequent years) did 
not distinguish between these different categories, hence 
the comparisons of outcomes among different types of 
inflammatory arthritis mainly relates to patients who had 
their primary surgery before 2007.
All 3 groups of inflammatory arthritis were classified 
regardless of their OA status. For the purpose of analysis, 
the comparison group included cases of OA where inflam-
matory arthritis had not been listed as a reason for surgery.
Procedures were excluded where OA or inflammatory 
arthritis was not recorded as an indication for surgery; 
where the data field relating to indication for surgery had 
not been completed; where any other indications for sur-
gery were recorded other than avascular necrosis; where 
no data had been completed on the implant type; and where 
surgery had been carried out for trauma. Subjects undergo-
ing simultaneous bilateral HA were excluded from the 
analysis of postoperative mortality. The data relate to the 
patients’ first recorded HA procedure: a small number of 
patients will have had a contralateral procedure prior to the 
start of the registry in 2003, but the exact numbers of these 
patients is not available.
Study outcomes
The study outcomes were:
1. The 5-year revision risk, defined as revision sur-
gery for any indication up to 5 years following pri-
mary HR and identified through record linkage 
within the NJR dataset.
2. The postoperative (90-day) mortality, defined as 
all-cause 90-day postoperative mortality based on 
record linkage to data from ONS.
The choice of the timing of end points was based on that 
standard practice of reporting for revision at intervals of 1, 
3, 5, 7 or 10 years: we chose the longest time point where 
we would have sufficient data to allow a meaningful anal-
ysis. Excess postoperative mortality has been shown to 
occur in the first 90-days after hip replacement.12
Statistical analysis
The 5-year implant survival and 90-day postoperative mor-
tality for all 3 groups of inflammatory arthritis were 
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compared with OA in a Cox proportional hazards regression 
models. Initially we considered minimally adjusted models, 
adjusted only for age and sex. We then compared these to 
adjusted models, which included American Society of 
Anesthesiologists (ASA) grade, year of operation, implant 
type (cemented or uncemented), and surgical approach 
(anterolateral, anterior, posterior or minimally invasive).
The 90-day mortality analyses also included thrombo-
prophylaxis (chemical or mechanical) and anaesthetic type 
(general or spinal) in the adjusted models. All results are 
presented as hazard ratios (HR) with 95% confidence 
intervals (95% CI) and p-values.
The variables included in the regression analysis have 
been recognised to influence revision risk and mortality 
following HA. Prosthesis fixation method (cemented ver-
sus cementless) is also recognised to influence revision 
rates for OA.11 We investigated if the effect of fixation 
method on the risk of revision varied for each of the differ-
ent inflammatory arthritis groups, by testing for the inclu-
sion of interaction terms in the multivariable adjusted 
models using likelihood ratio tests.
In sensitivity analyses we examined if further adjust-
ment for body mass index (BMI) affected the results. We 
used multiple imputation with chained equations to 
account for missing BMI data.13 As BMI was not collected 
in the NJR before 1 April 2004, it was assumed that BMI 
was missing completely at random, and these procedures 
were excluded from the imputation analyses. Imputation 
analyses were conducted for data relating to primary pro-
cedures where BMI had been recorded and any missing 
values were assumed to be missing at random. We included 
all covariates in the fully adjusted analysis model, a vari-
able to indicate revision, and the Nelson-Aalen cumulative 
hazard estimate in the imputation equations for BMI. A 
total of 1000 imputations were completed.
A competing risks survival analysis was also conducted 
with mortality as the competing event. Sub-Hazard ratios 
(SHR) were estimated for 5-year implant survival for RA 
compared to OA using the Fine and Gray method.14 The 
statistical analyses were carried out using Stata 14.15
Results
Characteristics of the sample
A total of 199,196 procedures were identified (Figure 1). 
We excluded 9080 procedures where OA or inflammatory 
arthritis was not recorded as an indication for surgery. We 
further excluded 3913 procedures performed for trauma or 
any other reasons except avascular necrosis. A total of 34 
procedures were excluded where implant type was not 
recorded. For the mortality analysis, we excluded a further 
2756 simultaneous bilateral procedures (1378 subjects).
A total of 186,169 procedures were included in the anal-
ysis of revision. Of these, Inflammatory arthritis was listed 
as an indication for surgery in 3061 (1.7%); RA: 1457, AS: 
615, otherIA: 1000. OA (with no associated inflammatory 
arthritis) was listed as the indication for surgery in 183,108 
(98.4%). There were 11 procedures in which >1 inflamma-
tory arthritis indication had been included.
Compared with OA, HA procedures carried out for RA 
were more likely to involve cemented components (Table 
1). Patients receiving hip operations because of inflam-
matory arthritis were younger, and had a greater level of 
comorbidity as indicated by an ASA grade 3 or above. 
Fewer resurfacing procedures were carried out for RA as 
an indication compared with OA. Those with RA and 
otherIA were more likely to be underweight than those 
with OA.
Risk of revision
The 5-year cumulative revision risk in those procedures 
undertaken for OA was 2.30% (95% CI, 2.23–2.37%). The 
unadjusted revision rates were all broadly similar to that for 
OA in all three inflammatory arthritis groups: (RA: 2.26% 
(95% CI, 1.62–3.17%), AS: 3.09% (95% CI, 1.98–4.80%) 
and otherIA 2.60% (95% CI, 1.78–3.80%)) (Figure 2). 
Table 2 shows the results of multivariate analysis. None of 
the models examined showed a significant difference in the 
hazard rate for revision for each of the three classifications 
of inflammatory arthritis compared with OA (adjusted 
model: RA: HR 0.93 (0.64–1.35; p = 0.70); AS: HR 1.14 
(0.73–1.79; p = 0.57); otherIA: HR 1.08 (0.73, 1.60)).
90-day mortality
The 90-day mortality rate in procedures carried out for 
OA was 0.52% (95% CI, 0.48–0.54%). Among the proce-
dures carried out for inflammatory arthritis the mortality 
rate in RA (1.13% (95% CI, 0.67–1.79%)) was higher 
than in OA while the rates in AS (0.67% (95% CI, 0.24–
1.72%)) and otherIA (0.30% (95% CI, 0.10–0.93%)) 
were broadly similar to the rate in OA (Figure 3). The 
increased 90-day mortality risk in RA was also reflected 
in the multivariate analysis (Table 3) where the age and 
gender-adjusted HR for RA compared with OA was 3.61 
(2.20–5.92; p < 0.001)), and remained significant after 
further adjustment for ASA grade, hip implant type, sur-
gical approach, year of operation, thromboprophylaxis 
(chemical or mechanical) and anaesthesia used. No sig-
nificant differences in postoperative mortality when 
compared with OA were found for AS (adjusted HR 1.56 
(0.59–4.18; p = 0.38)) and otherIA (adjusted HR 0.64 
(0.16–2.55; p = 0.52)).
Sensitivity analyses
Interactions. We found no evidence of an interaction 
between implant type and arthritis type on revision risk: 
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p-values for interactions were 0.13 for RA, 0.26 for AS, 
and 0.47 for otherIA.
Multiple imputation and further adjustment for BMI in the 
analyses of revision risk in RA. BMI was missing for 82% of 
the procedures overall. Imputation based on 164,560 proce-
dures where BMI data were assumed missing at random 
showed that additional adjustment for BMI resulted in a 
HR of for revision in RA compared with OA of 0.94 (0.64–
1.36; p = 0.73). This compared to HR 0.93 (0.64–1.35; 
p = 0.70) in the original multivariable model, suggesting 
that BMI does not have a material influence on the results.
Competing risks in the analyses of revision risk in RA. When 
mortality was treated as a competing with the risk of revi-
sion, the HR for 5-year implant survival among procedures 
undertaken for RA compared with OA was 0.97 (0.66–1.41; 
p = 0.86). This was similar to the findings in models in 
which competing risks were not considered.
Discussion
This national registry-based study shows that the risk of 
revision within 5 years of HA in patients with RA, AS or 
other types of inflammatory arthritis is similar to that seen 
in patients with OA alone. The findings contrast with the 
results of observational analyses that have suggested that 
the risk of revision is higher in patients with inflammatory 
arthritis and with the meta-analysis which showed an 
increased unadjusted risk of revision.5 The previous litera-
ture on the risks associated with joint replacement in RA 
attributed the increased risk of early revision to infection 
Figure 1. Population flow chart.
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and dislocation.6,16 Our data suggest that, despite poorer short-
term patient-reported outcomes,17 patients with RA undergoing 
joint replacement have similar implant revision rates as those 
with OA over the mid-term up to 5 years post procedure.
In contrast to the risk of revision, the 90-day mortality 
risk in patients undergoing these procedures enrolled on 
the NJR was not similar among these groups of patients. In 
patients with RA, while the overall risk of mortality fol-
lowing HA was low (1%), the 90-day mortality risk was 
almost threefold higher than in patients undergoing HA for 
OA alone. For AS and other types of inflammatory arthritis 
the mortality risk was similar to that observed in patients 
with OA alone. Patients with RA undergoing HA were 
younger than those with OA in our cohort and had a higher 
Table 1. Patient characteristics and implant type.
OA RA AS Other inflammatory 
arthropathy
 n % n % n % n %
All 183,108 98.4 1457 0.8 615 0.3 1000 0.0
Age (years) <55 18,674 10.2 331 22.7 154 25.0 309 30.9
55–59 17,905 9.8 202 13.9 72 11.7 130 13.0
60–64 25,634 14.0 236 16.2 86 14.0 116 11.6
65–69 32,059 17.5 247 17.0 93 15.1 144 14.4
70–74 34751 19.0 206 14.1 75 12.2 123 12.3
75–79 28,717 15.7 141 9.7 69 11.2 101 10.1
⩾80 25,368 13.9 94 6.5 66 10.7 77 7.7
Gender Female 108,771 59.4 1142 78.4 279 45.4 717 71.7
Male 74,337 40.6 315 21.6 336 54.6 283 28.3
ASA grade P1: Fit and healthy 43,913 24.0 125 8.6 114 18.5 172 17.2
P2: Mild disease no incapacitating 115,746 63.2 772 53.0 381 62.0 574 57.4
P3: Incapacitating systemic disease 22,443 12.3 538 36.9 114 18.5 237 23.7
P4/5: Life threatening disease 1006 0.5 22 1.5 6 1.0 17 1.7
Hip type Cemented 84,175 46.0 824 56.6 234 38.0 430 43.0
Uncemented 51,664 28.2 315 21.6 207 33.7 297 29.7
Hybrid 25,581 14.0 233 16.0 87 14.1 178 17.8
Reverse Hybrid 2548 1.4 26 1.8 7 1.1 8 0.8
Resurfacing 19,140 10.5 59 4.0 80 13.0 87 8.7
Surgical 
approach
Not posterior 88,867 54.4 704 56.3 313 50.9 468 52.6
Posterior 74,442 45.6 547 43.7 302 49.1 421 47.4
Year of 
operation
2003 13,211 7.2 142 9.7 0 0.0 77 7.7
2004 25,440 13.9 245 16.8 66 10.7 163 16.3
2005 36,565 20.0 323 22.2 153 24.9 199 19.9
2006 42,784 23.4 343 23.5 149 24.2 231 23.1
2007 51,626 28.2 306 21.0 216 35.1 250 25.0
2008 9726 5.3 74 5.1 21 3.4 57 5.7
2009 2434 1.3 17 1.2 8 1.3 14 1.4
2010 1151 0.6 5 0.3 2 0.3 8 0.8
2011 171 0.1 2 0.1 0 0.0 1 0.1
BMI (kg/m2) 
category
Underweight (⩽18) 10,753 5.9 107 7.3 35 5.7 79 7.9
Normal (19–25) 438 0.2 13 0.9 1 0.2 15 1.5
Overweight (26–30) 12,550 6.9 71 4.9 32 5.2 57 5.7
Obese (>30) 8311 4.5 33 2.3 20 3.3 30 3.0
Missing BMI 151,056 82.5 1233 84.6 527 85.7 819 81.9
OA, osteoarthritis; RA, rheumatoid arthritis; AS, ankylosing spondylitis.
Figure 2. Implant survival according to type of arthritis.
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ASA grade than those with OA undergoing HA. The 
increased mortality risk in RA was independent of patient, 
implant, and surgical variables.
An increase in 90-day mortality was also seen among 
patients with inflammatory arthritis in an earlier analysis 
in the NJR dataset. Unlike the present study, the earlier 
analysis did not distinguish between the type of inflamma-
tory arthritis.12 The observed increase in early postopera-
tive mortality amongst patients with RA is supported by 
previous reports suggesting an increased risk of 90-day 
hospital readmissions related to infection (both local and 
systemic)18 and serious pulmonary events including need 
for mechanical ventilation.8 A systematic review of the lit-
erature suggests that the observed excess mortality might 
not appear immediately after surgery (in the first postop-
erative month) but rather in the following 2 months.19 
However, our Kaplan Meier mortality data do not support 
this observation in this larger cohort.
Data on outcomes of joint replacement for individual 
types of inflammatory arthritis other that RA are sparse. A 
recent study on short-term outcomes following HA in AS 
has suggested that despite worse pre-surgery pain and 
function, 2-year patient-reported outcomes improved to 
equal those of patients undergoing similar surgery for 
OA.20 Our data are consistent with this, and showed no 
increased risk of either revision risk or 90-day 
postoperative mortality in AS patients compared to those 
undergoing HA for OA. The contrast in mortality between 
AS and RA may reflect the relative lack of comorbidity 
and general fitness in AS compared with RA, and may not 
have been fully accounted for in the multivariate model. 
Although no additional clinical data are available on these 
cases, it is likely that a smaller proportion of patients with 
AS will have been receiving disease modifying agents 
including biologics that may render them less susceptible 
to infective complications.
Our study has a number of limitations. The definition of 
arthritis type is a potential source for misclassification of 
exposure. It is however to be expected that surgeons would 
have coded this variable based on patient records, which 
should limit errors. The study outcomes (revision and 
death) cannot be validated at an individual level, although 
this should not affect the analysis of mortality, as date of 
death was obtained through record linkage. The cause of 
death could not be identified in the data available. Data on 
BMI were missing for a high proportion of patients. 
However, our sensitivity analysis found BMI had no 
impact on the observed associations. The problem of con-
founding by indication, where the choice of implant might 
be determined by patient characteristics, is also potentially 
limiting. We note, however, that adjustment for implant 
type had no material influence on our findings. While the 
confidence intervals for the estimates obtained for revision 
and mortality risks are relatively narrow, the findings also 
need to be tempered by power considerations. The study’s 
power also precluded us from addressing the influence of 
fixation type or individual reasons for revision.
The strengths of this study include the large sample size, 
and the length of follow-up available. Including potentially 
all patients and treatment centres in the NHS limits the 
potential for selection bias in previous cohorts. The findings 
are likely to be generalisable to Western European, 
Australasian and North American cohorts which exhibit sim-
ilar demographics and follow similar treatment strategies.
Conclusion
This is the first study to be conducted on sufficiently 
large scale to provide robust data on the rates of revision 
Table 2. Hazard ratios for revision according to arthritis type (compared with OA).
Reason for surgerya Adjusted for age and gender Fully adjustedb 
 HR 95% CI p-value HR 95% CI p-value
Seropositive RA (n = 1457) 0.796 0.565–1.122 0.193 0.929 0.64–1.351 0.701
Ankylosing spondylitis (n = 615) 1.078 0.687–1.693 0.743 1.141 0.727–1.792 0.566
Other inflammatory arthritis (n = 1000) 0.874 0.594–1.286 0.494 1.081 0.734–1.593 0.692
HR, hazard ratio; CI, confidence interval; OA, osteoarthritis; RA, rheumatoid arthritis.
aIncludes procedures that also had OA recorded as a reason for surgery.
bAdjusted for gender, age, ASA physical status grade, hip replacement type, surgical approach and year of operation.
Figure 3. 90-day patient survival according to type of arthritis.
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and postoperative mortality following HA in UK patients 
with different types of inflammatory arthritis. The find-
ings will be of importance to patients and surgeons con-
templating surgery for end stage disease of the hip. They 
also highlight the need to better understand the causes of 
the excess mortality risk in RA, and the impact of poten-
tial measures (specialised treatment centres or closer out-
patient monitoring following discharge, amongst others) 
to minimise postoperative mortality amongst those 
undergoing HA for RA.
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